Type 1 diabetes (T1D) is one of the fastest-growing, noncommunicable, chronic health conditions on the planet. 

How Common is Type 1 Diabetes?

1.5 million
People living with T1D in the U.S.
9.5 million
People living with T1D globally
199,000
Americans living with T1D under the age of 20
45-65
Age range of most Americans living with T1D

Demographic Research Findings about T1D in the U.S.​

Recent T1D Breakthroughs

2022

Type 1 Diabetes Disease Modifying Therapy

First Disease-Modifying Therapy for T1D Approved by the FDA

Backed by Breakthrough T1D, Tzield (teplizumab-mzwv), the first therapy to delay the requirement of insulin therapy for T1D, is approved by the FDA.

Read More About This Groundbreaking Therapy

2024

Project ACT Cell Therapies

Project ACT Launches

Project ACT (Accelerate Cell Therapies) is launched to speed up cell therapy research projects, advocacy work, and clinical adoption.

Learn More About Project ACT

2025

Young girl with type 1 diabetes shows off her new Barbie doll with type 1 diabetes

Debut of Barbie with Type 1 Diabetes

Breakthrough T1D, in partnership with Mattel, debuted the first Barbie with type 1 diabetes, raising awareness for the T1D community.

Learn More About Barbie With Type 1 Diabetes
Image of box of insulin pens

Civica Long-Acting Insulin Available in 2026

Civica Rx, a Breakthrough T1D-funded non-profit insulin manufacturer, announced affordable insulin at no more than $55 for five pens of long-acting insulin.

Read More About Civica

2026

Healthcare provider holding a vial of teplizumab (Tzield), the first FDA-approved disease-modifying therapy for type 1 diabetes

Tzield Receives FDA Approval for Label Expansions 

Backed by Breakthrough T1D, Tzield, the first treatment shown to delay the need for insulin therapy for T1D, received FDA approval for label expansions in 2026, extending its use to younger children with Stage 2 T1D and introducing a new indication for children recently diagnosed with Stage 3 T1D.

Dr. Piotr Witkowski shares clinical trial results

Promising Cell Therapy Clinical Trial Results

Vertex and Eledon Pharmaceuticals report promising cell therapy results that could move T1D closer to a functional cure. Vertex’s cell therapy was made possible by earlier support from Breakthrough T1D and the T1D Fund, and we’re directly supporting Eledon’s research today.

Read More About Eledon's Clinical Trial

Insurance Coverage for People with T1D in the U.S.

Other & Uninsured: 8
Medicaid: 13
Medicare: 28
Commercial Health Plans: 46
Commercial Health Plans
Medicare
Medicaid
Other & Uninsured

T1D Technology Use in the U.S.*

Treatments and technology for type 1 diabetes—including continuous glucose monitors (CGMs) and insulin pumps—have improved quality of life, but access to coverage and adoption is limited.

*Between 2021-2023

Continuous glucose monitors (CGM)

Insulin pumps

T1D Technology Access

If everyone around the globe had access to technology that automates glucose monitoring and insulin delivery, 741,000 more people could be alive in 2040. 

If everyone in the United States had access to devices, we would restore another 5.8 healthy years to the average person with T1D.

Insulin pump usage has become more prevalent in the U.S., but research shows pumps are less common among people of color with T1D and among people with government insurance coverage in the U.S.

Our Mission to Drive Toward Cures while Improving Lives

500+
Active T1D research projects funded to improve health outcomes
300
Cell therapy research projects funded to accelerate progress toward cures
$1.2 billion+
Amount invested from 2019-2025 directed to cure T1D and improve lives with the majority—approximately 82%—focused on cures.
$50 billion+
Government savings in healthcare costs thanks to the bipartisan-supported and Breakthrough T1D-championed federal Special Diabetes Program (SDP).
Screening to reduce DKA

In 2026, Breakthrough T1D convened an internationally supported paper that outlines the first framework for implementing general population screening for T1D in clinical practice. T1D screening programs, combined with long-term monitoring, can reduce life-threatening diabetic ketoacidosis (DKA) at diagnosis from 15-80% worldwide to less than 5%.